Intellia Therapeutics has Regeneron in its corner. (Marcos Silva/iStock/Getty Images Plus)
Massachusetts-based Intellia worked with sites in Europe and New Zealand to study the drug candidate, NTLA-2001, in a phase 1 trial. Having shown the candidate may safely reduce levels of misfolded TTR, a protein that drives the rare, life-threatening disease ATTR amyloidosis, the biotech has secured the FDA’s blessing to include U.S. sites in an upcoming phase 3 trial.
Intellia is aiming to start the global phase 3 trial by the end of the year, keeping it on track to achieve the timeline it set out in August. In a statement, Intellia CEO John Leonard, M.D., said the planned study will mark “the first in vivo CRISPR-based candidate to begin late-stage clinical development.” Editas Medicine paused its lead in vivo candidate, EDIT-101, after reporting phase 1/2 data 11 months ago.
The statement about the FDA clearance lacks details of the design of the NTLA-2001 phase 3 trial. David Lebwohl, M.D., chief medical officer at Intellia, gave investors a rough idea of what to expect on a conference call in August, explaining that it will be a “pretty similar” size to Alnylam’s HELIOS-B study.
Alnylam has enrolled 655 ATTR amyloidosis patients in HELIOS-B, a placebo-controlled phase 3 trial that is designed to validate vutrisiran in the indication. The RNAi therapeutic is one of several molecules that are in development or approved for use in ATTR amyloidosis.
BridgeBio Pharma shared phase 3 data on its candidate, acoramidis, earlier this year, while Ionis Pharmaceuticals, Pfizer and other companies are also active in the space.
Intellia has Regeneron in its corner. Under the terms of the partnership, Intellia is taking the lead on the development and commercialization of NTLA-2001, and Regeneron is covering around 25% of the costs in return for the same share of the profits.
Source: https://www.fiercebiotech.com/biotech/intellia-gets-fda-ok-trial-vivo-crispr-therapy-us-teeing-23-start-phase-3-trial
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
Plasmids GMP Services
AAV GMP Services
